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Abstract 
User innovation has been extensively and increasingly involved in the health sector in recent 
years.  As a typical performance, patients and caregivers develop innovative solutions beyond 
professional medical treatment, aiming to better respond to the diseases. In addition, some of 
those innovations are shared with other patients in need, through non-commercial and 
commercial approaches. In practice, PI (www.patient-innovation.com) platform was 
established in 2014 in Portugal, on which 850 innovations from patients, caregivers and 
collaborators are shared, fulfilling the mission of adding value to other people’s lives. 
With the huge population base, there has been great diversity and significant regional 
differences in living, health and medical conditions among Chinese nations. Taken also the 
limited Reimbursement ratio of medical insurance, as well as the exposure to increasing 
innovation activities in recent years in China into account, those possibly act as incentives for 
patients and caregivers to develop innovated, alternative solutions besides medical treatments. 
In this research project, we will focus exclusively on the patient innovation (PI) activities in 
China, thanks to its great potential. We aim to understand the following questions: 1. Do PI 
activities actively happen in China? 2. What are the findings and typical examples of PI 
activities in China? 3. What are the characteristics of PI activities and the influencing factors of 
PI in China? What are the differences of PI China comparing with those in developed countries? 
Given the complexity of the research and the limitations of the information sources, in our 
research work, both a multi-case study (online search for publicly available PI activities) and a 
quantitative approach (survey among patients with chronic disease and caregivers) are applied. 
55 online-available PI cases and 509 survey samples have been collected from China, which 
we’ve then screened and identified PI activities for further evaluation and statistical analysis.  
Our results have indicated a relatively activeness of PI activities in China with many practical 
examples. 1/3 patients or caregivers have reported innovation initiatives, and according to 
medical professionals, 13,5% have got a solution considered as reasonable, and 13,3% holds a 
meaningful idea, with many constraints possibly hinder implementation. Those PI activities has 
significantly improved the health and life quality, and some are shared with other people in 
need. Certain factors such as educational level and geographical region are likely to influence 
PI activities in China. In addition, PI activities in China shares some characteristics and 
influencing factors of those in Portugal, despite relatively simple and lower in technical contents. 
Keywords: User innovation, Healthcare, Patients, Caregivers, Chronic disease, China 
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1 Introduction  
1.1 Context and Research Theme  
User innovation has over the years been extensively involved in the health sector (Oliveira and Canhão, 
2014; Trigo, 2016; Gabriel et al., 2017) A stream of research studies (Czernin, 2013; Engström, 2014; 
Oliveira et al., 2015; Souliotis, 2016; Canhão, Zejnilovic and Oliveira, 2017) have indicated that, very 
often, patients, especially those with chronic disease and their caregivers have developed innovative 
solutions other than professional medical treatment. Those solutions helped to improve the patients’ 
treatment efficacy, physical conditions and life quality at varying degrees. In addition, quite a number 
of innovators are continually improving their solutions and sharing them with other patients and 
caregivers in need, either for free, at marginal cost or through commercial approach - by themselves 
and/ or with external collaborators. 
In practice, PI (www.patient-innovation.com, founded by Oliveira and Canhão, 2014) - an open, multi-
lingual, multi-national and not-for-profit platform has been established in Portugal, which enable the 
patients, caregivers and collaborators to share their solutions and actively communicate with other 
innovators, in the objective of improving the lives of other patients struggling with similar diseases. By 
far, the platform has over 500.000 visits, 850 medically screened innovations from over 60 countries, 
1600 submissions and 60000 users 5 continents. 
Owing the greatest population base and the diversified health condition among nations (Deloitte, 2014), 
in China, there 350 million people suffered from various chronic diseases and have physical disabilities 
at different levels. Although medical insurance has reached 95% coverage in China (Yu, 2015), public 
health insurance still covers less than 50% for serious and chronic illnesses on average (Various 
information sources, 2010-2017), and economic pressure would likely be an incentive for patients and 
caregivers to develop alternative low-cost solutions. On the other hand, China’s innovation capacity is 
also evolving among the years (McKinsey, 2015; McKern, 2016). With intensive and extensive exposure 
to innovation, patients, caregivers and others who have noticed a problem or need of patient are likely 
to be inspired to develop creative solutions. 
The above facts, and also taken the limited efficacy of medical treatment for certain type of diseases into 
account and also the scarcity of study in patient-centralized innovations in China has motivated us to 
implement this research project, through which we aim to understand better the patient innovation 
activities in China, especially those from patients and caregivers, what are the characteristics, specific 
examples and the difference between the PI activities in developed countries. We are also pleased to 
enrich the PI platform with innovations from China and adapting partially Chinese content. Together 
with the study of user innovation in healthcare from developing countries (Silva, 2017), we believe our 
research will add up crucial elements to the user innovations in the healthcare sector globally, as well as 
improve sharing on Patient Innovation platform between innovators from China and other countries. 
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1.2 Objective of Research 
In this research project, we will focus exclusively on the patient innovation activities from China. A 
combination of multi-case study and quantitative approach has been applied. Literature research, search 
and screen of online resources (search engines, forums, social medias and multiple databases), survey 
design and sample collection, evaluation following the advices from medical professions, statistical 
analysis, sharing solutions on the PI platform and translation of PI Awards page and respective solutions 
into Chinese will be carried out during this research project. 
The project will main focusing on the following research questions: 
1. Do PI activities actively and extensively exist in China? What are the best approaches to identify them? 
2. What are the findings for online-available patient innovations? What are the typical examples? What 
are the percentage and extent that patients and caregivers in China hold an innovative idea or solution? 
3. What are the main characteristics of PI activities in China? What are the barriers, positive effect and 
diffusion of PI in China? What are the influencing factors with PI activities in China? What are the 
differences between the PI activities in China compared with those in developed countries? 
The following sections include an extensive Literature Review in Chapter 2, a detailed description on 
the methodology for data collection and analysis in Chapter 3, and followed by result and in-depth 
discussion of online-available PI activities in China and survey among patients and caregivers in China 
in Chapter 4. Lastly, we will summarize the findings of this project and highlight the limitations and 
future research directions of our study in Chapter 5. 
 
2 Literature Review 
2.1 User Innovation in healthcare 
2.1.1 User innovation in the healthcare sector 
First proposed in 1976 by Von Hippel, the user innovation concept and phenomena has attracted interests 
from scholars for decades. User innovators are individual firms and consumers that expect to gain 
benefits from using their innovation as service or product; while on the other side, the producer and the 
service provider expect to gain benefits from selling the service or product (Blaya, Fraser & Holt, 2010). 
The user innovation has an important feature of matching the exact needs of users, other than adapting 
to the existing services or products. The huge potential of user innovation has been aware of by 
mainstream companies (Hippel, 2011). In additional, many individual consumers are able to make 
innovation for themselves as the technology development (Van der Boor, Oliveira & Veloso, 2014). As 
a result, user innovation has been beneficial to all the stakeholders including users, policy makers and 
manufacturers, and evidently indicates a paradigm shift from producer to user.  
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User innovation has also playing been an increasingly important role in the healthcare industry. Shields 
& Rangarjan (2013) has differentiated the professional users such as nurses and physicians from the 
non-professional users such as relatives and families of patients and patients themselves based on the 
study of the user innovation in the healthcare industry. The special needs faced by users and can be 
considered as a driving force for the development and generation of new solutions, a practical example 
is patients with some type of rare diseases tend to find possible solutions to the problem and serve 
themselves (Baker & Nelson, 2005). Snowdon, Bassi, Scarffe & Smith (2015) investigated that about 4-
6 % of UK, Finland, Japan citizens has created or modified services and products for personal use, and 
7 % of these innovations can be classified into healthcare products. Déglise, Suggs & Odermatt (2012) 
also reported that there is a positive relation between the influence of a solution on the overall quality of 
life of respondents and the possibility of the sharing of solution. Trigo (2016) provides an extensive 
review on the changing role of users in healthcare innovation, and have demonstrated the positive 
outcomes of treatments upon patient-involvement or patient-centred innovation. Gabriel et al. (2017) 
explores examples of open innovation in the field of health worldwide: companies, governments, 
researchers and citizens are collaborating to improve the innovation process, through which problems 
are identified, products and services are created and then adopted by the healthcare providers. 
 
2.1.2 Patients and caregivers as innovators 
Patients and caregivers are frequently found to be the driving force of innovation. Bodenheimer (2005) 
found that the active participation of patients can promote and drive institutional research. Bogers, Afuah 
& Bastian (2010) used to showed that this aspect is not sufficiently investigated. However, a serious of 
follow-up studies have investigated the roles of patients and caregivers as consumers of health with the 
motivation and capacity to innovate. As explained by Shcherbatiuk & Oliveira (2012), “Caregivers and 
patients innovators are people who make innovation to overcome barriers and difficulties that are 
imposed by their disease and consequently to improve their life quality”, and further study has indicated 
that the patient innovators have proposed new medical or non-medical treatment, strategies, and 
equipment to help them better deal with their disease (Oliveira, 2014). Agarwal & Shah (2014) has 
drawn a medium conclusion that the caregivers and patients have developed and invented many valuable 
solutions to their own diseases to improve their personal health situations. Such conclusion are verified 
by a stream of studies before and afterwards (Czernin, 2013; Engström, 2014; Oliveira et al., 2015; 
Souliotis, 2016; Von Hippel et al., 2016; Canhão, Zejnilovic and Oliveira, 2017), as a typical example, 
the study of von Hippel (2016) has investigated 500 respondents with rare diseases, of which 36% of 
these respondents claimed that they have created an innovative solution and 8% of them are considered 
to have introduced some new things into the world, according to the medical professionals. Some 
evidences of innovation made by patients show a strong influence on practices related to diseases and 
some demonstrate the state of art technology. 
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Moreover, with the aging population and decreasing birth rate especially in developed countries, the cost 
and expenditure of healthcare services are also increasing. As a result, user innovation can be a possible 
solution to such problem (Oliveira & von Hippel, 2011). Innovation made by patients and caregivers 
can help to generate a reform on the sector. There are three situations when the patient innovations are 
common. They are the dead-end situations, strong constraints on daily life and rare conditions (Ranck, 
2011). The patients’ innovation is more likely to happen in the situation when the disease is considered 
as severe. In addition, people who are suffering from chronic diseases tend to have higher needs of health 
and they are usually living in constraint reminders of their restrictions and they suffer from a decrease 
of life quality (Oliveira et al., 2015 & 2017). This explains the reasons that improving the quality of life 
is a large challenge and it is important to deal with this problem timely. 
In general, the innovations by patients and caregivers are generating huge influences on their life and 
providing supports to other patients and their caregivers in the process as well. The patients and 
caregivers can embrace a powerful role and a game changer in the healthcare industry.  
 
2.1.3 Diffusion and barriers of innovation from patients and caregivers 
Just as other user innovators, patients and caregivers also face certain diffusion decisions and challenges. 
When patients restrict their novel solutions and methods to personal usage without sharing, it prevents 
and prohibits other people from experimenting and improving them (Taylor, 2015). Moreover, diffusion 
is quite important and relevant since these innovations can help to improve the quality of life of these 
patients in the healthcare paradigm and decrease the costs related to the healthcare. In some situations, 
it can even generate a huge difference between dead and life situations. For example, the British 
Engineer Tal Golesworthy is a patient innovator who fixed his heart problem through generating a 
mechanism to sustain his aorta; Louis Plante who developed the frequencer to tackle his cystic fibrosis 
(Zurovac, Talisuna & Snow, 2012) is another example. These two patients were able to develop things 
not only to satisfy their own demands, and since they shared these solutions and resources to other 
patients, they are able to save the life or significantly improve the life quality of other people. The 
invention of Golesworthy have saved the life of 41 people so far, and many people in Canada, US and 
other countries are using the innovation of Louis Plante.  
On the other hand, since the user innovations are developed mainly for personal use, diffusion may not 
happen or even fail many situations. A number of caregivers and patients have developed innovations 
while they do not diffuse (Oliveira & Canhão, 2014). Under such condition, their innovation dies there. 
Those potentially useful solutions are not shared and others have to independently develop new 
innovation when they have similar needs. Another possible reason of low diffusion rate is the decrease 
of social welfare, according to the study of Dul & Hak (2007), which indicates that only 28% of people 
have ever made efforts to inform other people and share their innovation with other patients. 
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Despite the strong need of innovation, there are still several barriers hindering caregivers and patients 
to implement their ideas. The level of education, experience, availability, expertise may help to explain 
the reasons that innovation by caregivers and patients is lower than innovation in the general population 
in commercial and industrial products, professional communities or services (Lüthje, 2005). Although 
caregivers and patients are likely to make more innovations in more severe or pressing situations, they 
may not be able to create or develop something new. Baldwin, Hienerth & von Hippel (2006) suggested 
the differences in the user involvement in healthcare sector in comparison with other sectors and the 
shortage of user innovation culture in the health sector are the major barriers for the user innovation.  
DePasse et al. (2016) identified the existence of six forces influencing innovation in healthcare sector. 
Those are the accountability, customers, technology, public policy, funding and industry players, in 
which certain system barriers would possibly affect the diffusion of innovation. Innovators may perceive 
that, industrial players are sometimes in shortage of incentives to promote or help to commercialize their 
innovations as those low-cost solutions would be a competitive product and lower the profits; at the 
same time, those non-professional solutions may be considered as authoritative as a threat to the powers 
and authoritative of the medical professionals. The position and mindset of certain players are likely to 
become barriers for the innovation and sharing process of patients and caregivers.  
The potential negative influences and legal aspects of some innovations are also relevant in some cases, 
which may act as hindering forces for the innovation activities of patients (De Jong et al, 2015).  
Another barrier is the complicated financial mechanism and approval as well as the dynamics between 
the regulators, insurances, doctors and hospitals (DePasse & Lee, 2013). There are also barriers related 
to the accountability and the needs to comply with strict regulations that usually requires long time and 
create effort to make the innovation from the patients or caregivers available to the market. 
 
2.2 PI (Patient Innovation) Platform 
Started as an academic research project with the objective to study user innovation (von Hippel, 1988) 
by patients and their non-professional caregivers (Oliveira et al., 2015) and funded by The Portuguese 
Science and Technology Foundation (FCT), Carnegie-Mellon Portugal Program and Pieter Pribila 
Foundation, Patient Innovation project was founded and led by Prof. Pedro Oliveira (Copenhagen 
Business School & Catolica SBE Lisbon) and Prof. Helena Canhão from the FCM - NOVA Medical 
School. As one of the project's outcomes, the online Patient Innovation platform (PI, www.patient-
innovation.com) was launched on February 7, 2014 in Lisbon, Portugal. The project is supported by a 
number of distinguished individuals, including Nobel Laureate Sir Richard J. Roberts, Eric von Hippel, 
Nobel Laureate Aaron Ciechanover, Katherine Strandburg, Robert Langer, Lee Fleming and Keld 
Laursen – has been served on the Advisory Board. The PI platform shares online contributors' ideas to 
help managing personal health issues and improve life quality. 
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In brief, Patient Innovation (PI) is an open, multinational and not-for-profit platform, which enable the 
patients, caregivers and collaborators to share their solutions (strategies, treatments, devices and 
knowledges) and interact with other innovators. PI is also a multilingual platform currently adapting 
English, Portuguese, German and part of Chinese contents. In 36 months, PI platform has reached over 
500.000 visits, 60000 users from 5 continents, and over 1600 solutions are submitted, of which 850 
medically screened innovations from over 60 countries are available online, curated and shared to 
improve the lives of others struggling with different health conditions. PI Awards was also launched 
with the objective of honouring all patients, caregivers and collaborators who have developed innovative 
solutions to cope with the challenges of their health condition and help others, and 17 solutions in patient, 
caregiver and collaborator category became the winner of 1st, 2nd and 3rd PI Awards in 2015-2017.  
Since its inception, PI has been extensively involved in the media (https://patient-innovation.com/in-
the-media) and has received numerous honours. In December 2016 Patient Innovation has won the 
Healthcare Startup Awards and was named "Non-Profit Startup of The Year” by the HealthCare Startup 
Society. The London Science Museum has selected Patient Innovation project as one of seven case 
studies to be featured in the exhibition 'Beyond the Lab: The DIY Science Revolution' which opened 
July 7, 2016 and will visit 29 European countries until the end of 2018. 
 
2.3 Health conditions and Healthcare system in China 
2.3.1 Healthcare in Developing vs. Developed Countries 
In general, huge differences exist in the healthcare between the developing and developed countries. 
(Surbhi S, 2015). The healthcare system is assumed to take the responsibility of maintaining and 
improving the health through the treatment, diagnosis and prevention of injury, illness, disease and other 
physical and mental impairment while actually, the healthcare sector in developing countries sometimes 
failed to take these roles (Chen, Chen & Zhao, 2012). Another significant difference is healthcare 
industry consumed different proportion of the economy in developing and developed countries. The 
healthcare accounted for a much larger proportion of the total GDP for developed countries: The 
proportion is as much as 17.7% in US, 11.8% for Netherlands, 11.5% in France and 11.3% in Germany. 
However, the proportion is usually smaller than 5% for developing countries (Gu & Zhang, 2006). The 
healthcare sector in developed countries have usually experienced a long period of development and 
optimization, though which a mature system is established to provide sufficient healthcare service to 
patients in need. On the other side, in developing countries, the healthcare sector is still exploring and 
improving, and usually faces challenges such as underdeveloped technologies, insufficient financial 
supports and the immature facilities and incomplete equipment in the development (Giuliano & Droms, 
2012). In addition, different from developed countries, cultural issues may be involved in healing and 
become an obstacle for the improvement of healthcare in developing countries (Ibeneme, 2017). 
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2.3.2 Current status of population’ health in China 
Since 1949, the population’ health in China has significantly improved (gapminder.org). The life 
expectancy has reached 79,9 for female and 73,4 for male in 2016 (Healthdata, 2018), and morality rate 
for infants and kid below 5 has been consistently reduced. From year 1990 to 2016, the Healthcare 
Access and Quality (HAQ) Index has an average increase of 2,4% annually (IHME, 2016). 
However, great challenges still exist: In China, there are more than 260 million people with various 
chronic diseases (Bloomberg, 2012), and 83 million people have physical disabilities at different levels 
(UN Enable, 2014). There are more than 100 million cigarette smokers and HIV-AIDS epidemics is 
estimated to more than 2 million in China (Yip & Mahal, 2008). In addition, the hepatitis B infection is 
also widely spread in China, with 10% of population contracted this disease. Moreover, there is an 
increasing obesity rate in the population. The obesity rate in China has reached 10.8% (Yip & Hsiao, 
2018), which is correlated with the risk of suffering from hypertension, hyperglycaemia, 
hyperlipidaemia and CVD (Cardiovascular disease). Public health problem also rises concern, such as 
environmental health degradation (air and water pollution), greater prevalence of non-communicable 
diseases and food safety issues (Huang, 2016). Furthermore, a few avian flu outbreaks among Chinese 
cities successively in recent years, which generate some panics among the residents (WHO, 2018).  
 
2.3.3 Healthcare system in China 
The healthcare system in China includes both the private and public medical institutions and insurance 
programs. Fundamental health insurance has covered 95% of population in China (Yu, 2015). However, 
the public health insurance normally only covers half of the medical expense and an even lower 
proportion of costs related to chronic diseases and serious diseases are covered (Wang et al, 2016). 
Currently, all major cities in China have hospitals specialized in comprehensive or specific areas and 
equipped with advanced, modern equipment and facilities (Tang, 2013). The best Medicare in China is 
still provided by a joint venture of international or oversea-trained experts and the best domestic medical 
care resources (mainly advanced, imported facilities) available in Beijing, Shanghai, Guangzhou and 
other first tier cities (internationalcitizens.com). They are usually expensive and may cost up to ten times 
in comparison with public hospitals and could not be reimbursed by public health insurance. Public 
hospitals and clinics with different qualities are available throughout the urban areas in China (Cheng, 
2008). Hospitals in China are organized according to a 3-tier, 10 level system that recognizes a hospital's 
ability to provide medical care, medical education, and conduct medical research, and the high-quality 
treatment can be expected in 3rd-tier, city-level hospitals (Li et al., 2008).  
Trend has indicated that China's medical system and quality are moving towards industrialized countries. 
In the past decade, Chinese government has implemented national health care reform to improve access 
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to essential services and reduce high out-of-pocket medical spending focusing on public hospitals 
(Barber, 2013). According to the Global Hospital Management Survey (2014), the overall average 
management score across large public hospitals in China was 2,86 on the 1-5 WMS management, 
slightly below the standard average score of 3 in US, but has exceed UK (2,82), Sweden (2,68) and 
Germany (2,64). Chinese hospitals demonstrated particular strength in standardization and operations 
management but acute weakness in talent management. 
In rural areas of China, healthcare services are provided by doctors with less medical experience, and 
limited medication and medical equipment are available. It is estimated that 80% of health and medical 
services are concentrated in cities, which means that timely medical care is not available to more than 
100 million people in rural areas (Chelala, 2013). Nevertheless, the rural health services in China have 
developed rapid in recent years with a significant improvement in quality (Liu, 2014). China's New 
Cooperative Medical Scheme (NCMS) was brought to life to reduce the inequity in access to health care 
in rural China (Yang et al., 2013). Chinese Health Ministry and Bayer HealthCare has launched “Go 
West” program aiming to provide 10,000 doctors for rural areas (mainly in undeveloped west part of 
China) with post-graduate medical training, Bayer is increasing its sponsorship and have invested the 
equivalent of a further US$ 3.09 million by 2017. 
In addition to the modern medical care and facilities, the traditional Chinese medicine (TCM) is also 
widely applied in China. Many Chinese medicine treatment facilities and hospitals are located in China, 
in addition, general hospitals are increasingly utilizing TCM strategies for chronic disease care and 
prevention (Fan et al., 2018).  
In recent years, problem such as unaffordable medication, insufficient medical resources in top-tier 
hospitals as well as health risks brought by urbanization such as air pollution and traffic hazards are 
rising concerns in China (Huang, 2016), but as well provide opportunities to improve. Since the late 
2000s, the Chinese government has pursuing a new round of healthcare reformation including essential 
drug policies, universal basic medical insurance, and detailed measures for public hospitals and 
community healthcare centres (Liu et. al, 2017). Based on an investigation, public healthcare services, 
but not private clinics are the priority choices among Chinese residents (Tang, Xu & Zhang, 2016). 
Under the "Healthy China 2020" initiative, China has been undertaking efforts to reduce healthcare 
costs, and the government requires that insurance will cover 70% of costs by the end of 2018 (NYTimes, 
2011). The main goal of Chinese government is to provide affordable basic healthcare to all residents 
by 2020 (China Business Review, 2011). 
The list of references we’ve reviewed and applied in our study are presented in Appendix A. 
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3 Methodology 
3.1 General methodology 
Given our initial research has indicated complexity and limited transparency of patient innovation (PI) 
activities in China, we’ve applied a combination of two approaches in our study:  
1) Multiple-case study, in which we’ve searched online for PI activities that are publicly available in 
China and combined the results from various information resources; results were screened and analysed, 
and specific cases were further studied and shared (partially in Chinese) on the PI platform. 
2) Semi-quantitative study, in which we’ve designed a survey targeting the patient and caregivers in 
China, to evaluate whether they have an innovative idea or developed innovative solutions to improve 
their health conditions. Samples were collected, translated, organized and classified according to the 
advices from medical professionals. Data were further screened and statistical analysis (general, Chi-
Square and ANOVA) are conducted using SPSS. Results are organize analysed in detail to identify the 
main characteristics and influencing factors of PI activities in China. 
 
3.2 Data collection method 
3.2.1 Online search for Chinese PI activities 
After initially screened a variety of online resources, including multiple search engines, patient 
communities (comprehensive and typical disease type such as lymphoma and spinal cord injury), social 
media and video websites, patent and academic databases etc., and also by discussing with other 
researchers in the PI platform, we’ve applied search engine as the main approach for online search and 
supplemented with other channels.  The main process and method are as follows: 
1) We’ve used Baidu (the most commonly used search engine in China) and Google, and searched for a 
combination of Chinese keywords related to patient innovation: patient + innovated, patient + innovation, 
patient + invented, patient + invention, suffered from disease + innovated/ invented/ innovation/ 
invention, disabled [or other chronic disease type] + innovated/ invented/ innovation/ invention, etc.; 
2) We’ve clicked further the links related to PI activities and checked carefully. If it’s likely to be related 
to PI, we would summarize the key information in an excel file, including topic, category (patient, 
caregiver, collaborator etc.), disease type, gender, region, solution, representative figures, etc. We also 
used specific keywords to search for other available resource of the same innovation, and recorded other 
useful information sources in the file;  
3) Database with potential PI solutions were further analysed, in which a number of representative 
solutions are shared on the PI platform and/ or selected for case study. In addition, all the related links 
are recorded, and unqualified / uncertain results were also discussed with medical professionals. 
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An example of the database structure of online-searched potential solution are presented in Appendix B. 
 
3.2.2 Survey among patients and caregivers in China 
For semi-quantitative analysis, a bilingual (English-Chinese) online survey targeting patients and 
caregivers in China was designed referring to the existed PI surveys (Czernin, 2013; Oliveira et al., 
2015) All questions were grounded in user innovation literature and verified by medical professionals.  
The survey was partitioned into 4 sections with 36 questions (part contains supplementary questions and 
sub-questions): 1) General questions: to identify respondent as patient or caregiver, type of disease and 
the related influences, as well as a screening question to identify whether the respondents has got an 
innovative idea and the stage (have idea only, developing an innovation, developed an innovation or 
have reached important milestone); 2) Innovation-related questions: this part is classified as 2a (for 
respondents with ideas only), to understand why the respondents didn’t go further with the idea, and 2b 
(for respondents developing or have developed a solution), to learn more about the motivations, 
influences and implications of innovation; 3) Demographic questions: this part includes gender and 
age of patients (innovators), location, employment status, educational level and marital status of all the 
respondents, as well as whether they’ve joined a patient community/ group and stay active; 4) ICT-
related questions: this part aim to measure the respondents’ exposure to Internet and Social media, as 
well as their willingness to join the PI community.  
In particular, we’ve taken the habitual and cultural differences into consideration and modified or 
redesigned a few questions to make it more adaptable to the Chinese background. E.g. For the 
effectiveness of treatment (Q5, Part 1), we include TCM as it’s still commonly used as main or auxiliary 
approach for the treatment of chronic diseases in China; Consider the huge regional differences, in Q29 
(Part 3) we include the location and administrative division of residence (~50 key and big cities, other 
prefecture level cities, counties/ towns and countryside). 
The complete questionnaire in this study with all the questions are presented in detail in Appendix C. 
 
3.2.3 Data collection 
Samples are collected in collaboration with GRT Market Research Co. (a listed company in China) after 
initial screening and inquiry of 15 companies. The company has a sample bank of 2.3 Mio active users 
with 19 diversified demographic attributes. The 1st question of the survey is used as a screening question, 
which only patients with chronic disease and their caregivers are eligible to answer the complete survey. 
798 collected samples were manually screened to remove those with repeat submission, same IP-address 
with highly similar contents, or obviously unreasonable and irrelevant answers. As a result, a total of 
509 sample from patients and caregivers in China were collected in 2 weeks. 
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Collected samples were manually screened and typos as well as nonsense words and symbols are 
corrected. In addition, due to the imperfections during survey design and data collection, data were fixed 
to pave the way for further analysis, the process for fixation of data are listed in Appendix D. The whole 
survey data were then translated into English using google translator and proofread manually. 
 
3.3 Data Analysis Method 
3.3.1 Primary evaluation for PI activities 
Primary evaluation of potential PI-relevant solutions was conducted based on the following criteria (s): 
1) Identification of Effective PI Solutions: All the 55 potential solutions are first justified by:  
a. Effectiveness: The solution has worked well and improved the health/ life of patients (caregivers). 
b. PI and sub-category: Whether a solution is considered as a PI activity and specific category (patient, 
caregiver, collaborator) with the help of medical experts and specialists, since some of the solutions are 
initiated or extensively involved by people with professional medical knowledge. 
Only those in line with the above 2 features are considered as Effective PI Solutions, and are evaluated 
further to justify whether they are qualified solutions; 
2) Evaluation of Quality: All the effective PI solutions are rated based on the following features: 
a. Innovative and/ or Uniqueness (based on the innovator’s knowledge); b. Likely to share among 
and/ or inspire other patients; c. Enough information and resources are available. 
Consider the enormous complexity of PI activities in China, for each feature we used 1 (clearly), 0,5 (to 
some extent) and 0 (almost no) for rating, and then we added up the scores for each solution. A solution 
that scored 2,5-3 is rated as “Good Example”, that scored 1,5-2 is rated as “Ordinary Example”, and that 
scored 0,5-1 is rated as “Limited Example”; 
Then a brief statistic of the solutions based on the above criteria plus gender and region information 
were conducted, and the main characteristics as well as specific examples are further discussed. 
For the unqualified and uncertain results, we’ve discussed all of them and explored some in detail, but 
finally chose not to include them in this study. Nevertheless, the main tendency and patterns of findings 
are used as supporting evidences in this study. 
 
3.3.2 Statistical Analysis for PI Survey 
Translated survey results were imported or inputted into SPSS Software (IBM, V23.0). A total of 502 
samples were imported, and the following adjustment, calculation or evaluation were proceeded: 
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1) Further Classification: For Q1 and Q2, we’ve classified the relationship of caregivers (7 categories) 
and type of diseases (16 categories), each as an independent variable; 
2) Multiple Choices: For Multiple choice questions (Q12, Q16, Q17, Q20, Q21, Q35), we’ve set each 
choice as an independent variable; 
3) Secondary Data: To enable further analysis, we’ve generated some new variables, including Average 
disease Burden (Q4), Average treatment efficiency (Q5), Number of disease(s) suffered (Q2), Number 
of social medias used (Q35), Joined patient association + group/ forums (Q32 and Q33); 
4) Rating of Ideas and Solutions: As some of the idea/ solutions are obvious nonsense or thoughts that 
are very unlikely to improve health or help others, we’ve screened and rated the 174 ideas and solutions 
following the guidance of medical professionals. Solutions are rated as: 1 – “Nonsense”; 2 – “Thoughts, 
but not qualified for PI”; 3 – “PI – Ordinary Example” and 4 – “PI – Good Example”. 
5) Screening of Ideas and Solutions: based on the rating, we’ve then selected all the ideas and solutions 
that are scored at 3 or 4, which we’ve considered to be valid PI ideas (N=67) and PI solutions (N=68), 
and the rest samples are considered to be “non-innovators” (N=367) in our further analysis.  
New variables (None | Idea), (None | Innovation), (None | Idea | Innovation) and (None | Idea + 
Innovation) are created to identify and classify different groups for statistical analysis in our next steps. 
Descriptive statistics (4.2.1-4.2.3) for variables were achieved using “Descriptive Analysis” tool in 
SPSS, values were recorded and organized in tables. For respondents with innovative ideas (4.2.2) or 
innovative solutions (4.2.3), sub-dataset was created to facilitate analysis. 
To analyse influencing factors of PI (4.2.4), Chi-Square and ANOVA analysis were conducted in SPSS, 
of which ANOVA (plus post-hoc) were used for ordinal and scaled factors such as Disease duration (Q3) 
and Number of social medias used (Q35), Chi-Square were used for nominal factors (mainly 
demographics) such as Marital status (Q31) and Educational level (Q29). p-values (Sig.) of all the factors 
in respective of different groups (Idea, Innovation, Idea + Innovation) were organized in table for further 
analysis and discussion, to justify whether a factor would affect PI activities in China. 
 
4 Results and Discussion 
4.1 Results for online-searched Chinese PI activities 
4.1.1 Extents and quality of online available Chinese PI activities 
Our initial screening has resulted in more than 100 results, however, the solution developed by medical 
experts (nurses, doctors, scientists), profit-oriented commercial products, and the solution with little 
information about the innovator and the innovations process are excluded. In brief, a total of 55 potential 
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PI-relevant solutions were recorded for further evaluation, of which ~95% are considered as effective 
and 45 (81,8%) are justified as Effective PI Solutions. 
Total PI-relevant Solutions Evaluated (N=55) 
Effective solutions 52 (94,6%) Effective PI Solutions 45 (81,8%) 
Figure 1. Extents and Quality of online-available PI solutions in China  
The majority (41 out of 45) of solutions are developed by male innovators; PI solutions are mainly from 
mainland China (39 out of 45), and also from Chinese people living in other countries. 
In China, PI Solutions are distributed across different categories: patient, caregiver and collaborator. 
The percentage are quite similar, with each account for ~1/3 of the total PI solutions. 
In terms of quality, PI solution under different categories are relatively similar, with about 3/5 of the 
solution rated as “Good Example”. “Limited Example” also exists (3 out of 45), but was found only in 
the patient and caregiver category, but not the collaborator category. 
Effective PI Solutions (N=45) 
   
*China refers to mainland China, Asia has excluded mainland China and world has excluded Asia. 
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4.1.2 3 Examples of PI activities in China 
Innovation example from Patient 
Yunlu Gao, a primary school student, was born in 2005 in Shenzhen, China. He was diagnosed of serious 
hyperopia and congenital phoria, which gradually developed into strabismus with age. The doctor said 
a surgery was required for his eyes and if he had not recovered at a certain age, non-surgical early 
treatment would be the solution to improve his condition. 
During his treatment, Yunlu Gao and his father learned as much as they could on strabismus through the 
internet and international ophthalmic books, through which they understood the key factors. After four 
years of hard work, Gao’s binocular vision has been effectively controlled, together with his binocular 
fusion function and strabismus. 
After recovery, he improved the detector further to help the patients with similar situation. The device 
can guide the rotation of the eye and analyse the muscle condition, and justify the results through 
comparison and data analysis. Besides, it can conveniently send the eye-related data through the Internet 
to the relevant professional medical institutions, and provide treatment plan for the patients. 
Gao’s eye muscle detection device has won the silver award in the 69th IENA invention exhibition in 
Nürnberg, Germany. His explanation on the principle of the invention, combining with his own 
experiences, has received high praise among the professional judges. Gao hopes he could share his 
treatment process and methods to help more people suffering from strabismus. 
 
Innovation example from Caregiver 
Xu Yin, born in 1995, currently studying at Nanjing Medical School in China, has developed an epilepsy 
alarm device for his grandmother together with his classmates. The device can send alarm when 
“clenching teeth”, a normal symptom of epilepsy occurs. 
Since childhood, Yin remembered that her grandmother suffered from epilepsy, which occurred every 
few months and usually during the night. “Normally, the whole family was asleep when my grandmother 
had seizures”, Yin recalled. In the early spring of 2017, his grandmother had seizures and Yin was 
extremely worried. At midnight, Yin came to an idea of developing a device to alarm the caregivers 
when the seizure occurs, and wrote down his initial plan at 2 am. 
Yin shared his idea with his classmates, and soon a group of five people started designing the device. 
Through consistent learning and improving, the device was finally developed in 2017. Once the patients’ 
epilepsy symptom last by more than 8 seconds, the device will send alarm sound to inform the caregivers. 
Yin’s group also designed a mobile app to record and manage the patients’ history of occurrence and 
conditions and enable the caregivers to keep track and share data with doctors. 
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The cost of the device is about 70 EUR. In addition to helping his grandmother, Xu and his group 
members have been busy pitching the epilepsy alarming device to medical device producers, and they 
hope they could soon bring the innovation into the market. 
 
Innovation example from Collaborator 
Nana Wang, born in 1994, and Shuang Huang, born in 1995, in China, are postgraduate students from 
top universities in China. To help Wang’s friend who suffers from hearing loss and other deaf people, 
they developed a translation armband, which can convert sign language into speech. 
Inspired by a deaf friend, Nana Wang and her friend Shuang Huang started developing a solution for 
people with hearing disorders in 2015. The armband collects the signals of sign languages, analyse 
through AI deep learning and finally convert them into speech. “It is extremely difficult to accurately 
recognize a gesture. Usually it requires to collect the signal for a thousand, even several thousand times.” 
explained the inventors. 
After two years of hard work and thousands of experimentations, they successfully developed a gesture 
recognition armband which recognize the most common 400 gestures from sign language. 
"In China, there are 70 million people with language dysfunction, for a variety of reasons”, said Shuang 
Huang, Nana Wang’s friend and roommate in the university, a student from Tsinghua University. 
Although currently the armband can only translate common gestures one by one, the students believe 
that they will be able to improve it with the fast development of AI. The sign language recognition 
armband has also won the championship in an innovative competition held by the United Nations and 
an Internet company. The girls said they are not thinking of making money out of their invention yet, 
but would be pleased to help more deaf people communicate normally. 
 
4.2 Results for survey among patients and caregivers in China 
4.2.1 General and demographic information of respondents 
Patients 
General and disease related information of 502 patients are summarized in Table 1-4. As indicated, the 
patient has an average age of 50,2 and 260 (51,8%) of which are women. The patients are suffering from 
1-4 chronic diseases (the majority only have 1 or 2 diseases), and the main type of diseases suffered are 
hypertension, asthma, diabetes, heart diseases/ CVD. The diseases have created strong negative impact 
on 43,3% of patients and 35,7% of caregivers, and the current medical treatments are quite ineffective 
for more than ¼ of patients. 373 and 90 out of 502 patients have a disease duration of 1-10 years and 
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more than 10 years, respectively. The diseases also increase monthly expense of more than 250 EUR for 
87 patients and 100-249 EUR for 208 patients (converted from local currency). 
 Gender of patient Birth year of patient 
 Female Male Max Min SD Avg. 
Value 260 (51,8%) 242 (48,2%) 2000 1920 14,6 1967,8 
     Avg. Age ~50,2 
Table 1. Gender and Birth year of Patients (N=502) 
 
No. of diseases suffered Type of diseases suffered (Top 5) 
 No. of patients (%)  No. of patients (%) 
1 disease 363 72,3% Hypertension 191 38,0% 
2 diseases 108 21,5% Asthma 117 23,3% 
3 diseases 27 5,4% Diabetes 107 21,3% 
4 diseases 4 0,8% Heart diseases/ CVD 98 19,5% 
Total 502 100.0% Osteoporosis 41 8,2% 
Table 2. Number and Type of Diseases Patients suffered (N=502) 
 
 Negative Impact Effectiveness 
 For the patient For the 
caregiver 
Western 
Medicine? 
Chinese 
Medicine? 
Portable 
devices? 
Average 3.28 3.10 2.95 2.94 3.00 
Strongly 
Negative impact 
222 (43,3%) 179 (35,7%) - - - 
Serious Flaws - - 130 (25,9%) 157 (31,3%) 160 (31,9%) 
Table 3. Disease Burden and Treatment Efficiency (N=502) 
 
Disease duration Increase in monthly Expense 
< 12 Months 18 Yes, but less than 100 EUR per month 197 
1 year (included) - 3 years 11 months 192 Yes, 100 (incl.) -250 EUR per month 208 
4 years (included) - 9 years 11 
months 
191 Yes, 250 (incl.) -499 EUR per month 63 
> 10 years (included) 90 Yes, 500 (incl.) -1199 EUR per month 16 
Not sure 11 Yes, > 1200 (incl.) EUR per month 8 
  No increase 10 
Total 502 Total 502 
Table 4. Disease duration and Increase in Expense (N=502) 
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Respondents (Patients or Caregivers) 
Socio-demographic information of 502 respondents are summarized in Table 5. As indicated, among 
which we have 215 patients and 287 caregivers with similar demographic properties. 370 (73,7%) of the 
respondents are employed, 86,7% are married, 71,7% have a university or higher degree, 92% have 
access to internet on a daily basis, 81,5% use 2 or more social media and 13,1% are a member of disease 
association (groups) and/ or visit/ post on disease forums.  
 Total (N=502) Patient (N=215) Caregivers (N=287) 
Employed 370 73,7% 169 78,6% 201 70,0% 
Married 435 86,7% 191 88,8% 244 85,0% 
University degree or above 360 71.7% 157 73,0% 203 70,8% 
Access to internet daily 462 92.0% 194 90,2% 268 93,4% 
Use 2 or more Social Media 409 81,5% 182 80,0% 237 82,6% 
Member of Disease Forum/ 
Association 
66 13,1% 26 12,1% 40 13,9% 
Table 5. Socio-demographic information of Respondents (N=502) 
 
As shown in Table 6, among the 502 respondents, 290 (57,8%) have never thought nor heard about an 
idea or innovation, 38 (7,6%) haven’t thought by have heard of innovative idea or solutions, and 174 
consider they’ve got an innovative idea or solution: of which, 104 (34,6%) respondents only have ideas 
but didn’t implement it (or tried but stopped), 61 are developing a solution and 9 have developed a 
solution or reached important milestone. 
 No. (%) Patient Caregiver 
Never and haven’t thought of it 290 57,8% 126 164 
Never, but know others did 38 7,6% 10 28 
Have idea but no action 104 20,7% 46 58 
Developing a solution 61 12,2% 28 33 
Developed a solution  9 1,8% 5 4 
Total 502 100%   
Table 6. Potential PI activities of Respondents (N=502) 
 
The type and quality of self-reported innovations are shown in Table 7. From which we could see that 
half (50,6%) of the idea and solution are behaviour/ habit/ strategy, the other types are treatment/ therapy 
(18,4%), food/ drink/ natural product (17,2%) and medical equipment (9,2%). According to medical 
professionals, the quality of idea or solution varies, with a higher % of low-quality examples in 
treatment/ therapy category. However, 79 and 56 are considered as “Ordinary Example” or “Good 
Example”, respectively, which in total account for 77,6% of self-reported data. 
 18 
 
 
No. % Nonsense Thoughts 
Ordinary 
Example 
Good 
Example 
A medical equipment 16 9,2% 1 2 3 10 
A Treatment/ Therapy 32 18,4% 4 11 10 7 
A Behaviour/ Habit/ Strategy 88 50,6% 2 5 51 30 
A food/ drink/ natural product 30 17,2% 1 6 15 8 
Others 8 4,6% 5 2 0 1 
Total 174 100% 13 26 79 56 
Table 7. Type and Quality of Potential PI activities (N=174) 
 
Due to limitations, specific example of innovative ideas or solutions would be included in our future 
study, and the full list of innovation description including rating is shown in Appendix E. 
 
4.2.2 Patients and caregivers with innovative ideas 
67 out of 104 ideas were rated as “Ordinary Example” or “Good Example” and included in our analysis 
of innovative ideas from respondents. As indicated in Table 8, only 17 of them have moved a few steps 
forward (10 have specified in a draft/ description and 7 once started working but stopped), but the 
majority haven’t taken any actions so far. Communication of ideas seems more likely to happen, nearly 
half (32) chose to share with family members and 1/6 (11) choose to share with other patients with 
similar disease. 3 have shared their ideas with doctors. However, 20 among them have never talked with 
anyone about their innovative ideas. 
Stage of innovative ideas Communication of innovative ideas 
Just thought about but no action 50 No 20 
Specified in a drawing/ written description 10 Yes, other patients with similar disease 11 
Started working on my idea but stopped 7 Yes, my family and relatives 32 
  Yes, other friends (non- patients) 1 
  Yes, my doctor(s) 3 
Total 67 Total 67 
Table 8. Stage and Communication of Innovative Ideas (N=67) 
 
What factors would prevent patient and caregivers from implementing their ideas? Table 9 has shown 
that “Perceive it’s difficult to execute” is the most common reason (50,7%), other important reasons are 
time constraints (41,8%), economic constraints (37,3%), physical constraints (32,8%) and others think 
it’s not interesting (23,9%). 
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Respondents with innovative idea (N=67) No. (%)/ Specific Reason 
Physical constraints (Disease related) 22 32,8% 
Time constraints 28 41,8% 
Economic constraints (cost) 25 37,3% 
Perceive it’s difficult to execute 34 50,7% 
Others think it’s not interesting 16 23,9% 
Other reasons 2 2,94% 
Table 9. Reasons for stop implementing Innovative Ideas (N=67) 
 
4.2.3 Patients and caregivers with innovative solutions 
68 out of 70 solutions were rated as “Ordinary Example” or “Good Example” and included in our 
analysis of innovative solutions from respondents. As indicated in Table 10, most of the innovations (50) 
takes 6 months to 5 years and the cost varies significantly, with 31 solutions cost no more than 1000 
EUR, 12 solutions cost 1001-3000 EUR and 11 solutions cost more than 3001 EUR. 
Duration of innovation Cost related to innovation 
Less than 6 months 11 Not specified or not significant 14 
6 months (included) – 1 years 11 months 31 0-200 EUR 9 
2 years (included) – 4 years 11 months 19 201-1000 EUR 22 
More than 5 years (included) 5 1001-3000 EUR 12 
Not sure 2 3001-10000 EUR 7 
  >10000 EUR 4 
Table 10. Duration and Cost (real or expected) of Innovative Solutions (N=68) 
 
As shown in Table 11, those solutions have significantly improved the life quality of patients. 49 (72,0%) 
have reported improved in life quality after the innovation versus medical treatment, the average score 
of life quality (based on 1-7 scale) has increased by 1,18 after the innovation. 
 Value/ No. 
 
Minimum -2 
Maximum 5 
No. of innovations (>1) 49 (72,0%) 
Mean 1,18 
Medium 1 
Table 11. Effectiveness of Innovative Solutions 
VS. Medical Treatments (N=68) 
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Table 12 indicates the collaboration and active learning during innovation. Very often, the innovators 
are working with their family members (69,1%) and friends (32,4%), other collaborates include students 
(17,6%), company (5,9%) and other kind-hearted people (5,9%). Active learning during innovation is 
also significant, 65 have learned new knowledge and 31 suppose they’ve learned a lot during the process. 
 
As seen in Table 13, 64 out of 68 innovators have discussed with other people about the innovation, 
including other patients with similar disease (16), family members and relatives (44) and other non-
patient friends (3). Only 1 innovator has ever discussed with the doctor. Some innovations are also 
known by public, 6 has participated in competition/ exhibitions and 8 were reported by media. 
Communication of innovation Innovation known by public 
No 4 No 55 
Yes, other patients with similar disease 16 Participated in Intl Competition 4 
Yes, my family and relatives 44 Participated in national/ regional 
competition 
2 
Yes, other friends (non- patients) 3 Reported by media 8 
Yes, my doctor (s) 1 Others 1 
Total 68   
Table 13. Communication & Public Awareness of Innovative Solutions (N=68) 
 
As seen in Table 14, besides 1 innovator, the rest 69 innovators are willing to share their innovations 
with other patients in need, of which 19 has already shared and worked on others and 28 are about to 
share with others. A certain % of innovators have positive attitude towards innovation, with 24 feel 
proud and improved confidence, 42 are planning to improve it further and 29 would like to share for free 
or with marginal cost. Moreover, 5 innovators would like to start business out of their innovation. 
Interestingly, 45 out of 68 innovators intend to apply for patents and 8 have already submitted 
application (none are yet granted). Of the 5 innovators as potential entrepreneurs, 3 are looking for 
manufacturers, 1 planning to start business soon and 1 is collaborating with manufacturers (Table 15). 
Help from others during innovation Active learning to develop the solution 
No 3 4,4% No 3 
Family 47 69,1% Yes, I’ve learned a little but not much 32 
Friends 22 32,4% Yes, I’ve learned a lot 24 
Students 12 
17,6% 
Yes, I’ve learned a huge amount and 
intensively/ consistently 
9 
Company 4 5,9%   
Others 4 5,9% Total 68 
Table 12. Collaboration & Active learning of Innovative Solutions (N=68) 
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Willingness to share innovations Personal Attitude to innovation 
I’ve already shared and it worked on 
others 
19 
Proud of myself, improved confidence 24 
I’ve talked and about to share with others 28 Planning to improve it further 42 
I’m happy to share with others, but 
haven’t yet due to constraints 
20 
Would like to share for free/ marginal 
cost 
29 
Currently haven’t considered sharing 1 Would like to start a business 5 
Total 68   
Table 14. Sharing and personal attitude to Innovative Solutions (N=68) 
 
Start a business out of innovation Plan and action on patents  
Planning to start/ cofound soon 1 No, and I’m not planning to apply 23 
Collaborating with manufacturer 1 No, but I’m planning to apply 37 
Looking for manufacturer 3 Have applied patent but not yet granted 8 
Total 5 Total 68 
Table 15. Plan of Business (N=5) and Patents (N=68) for Innovative Solutions 
 
4.2.4 Factors that influences innovative ideas and solutions 
In this section we aim to explore the influencing factors of PI activities in China. Although both 
innovative idea and innovative solution are considered as PI activities, however, since they belong to 
different stages of innovation and the respondents’ initiative and the time/ effort involved are likely to 
be different in those two categories. Therefore, we’ve analysed “Innovative Idea”, “Innovative Solution” 
and “Innovative Idea+ Solution”, respectively, versus the “Non-innovation” group to identify the 
possible influencing factors of PI activities in China. Results for the significance of nominal and ordinal 
factors corresponding to each aforementioned group are shown in Appendix F. 
As indicated in Table S2, “negative impact of disease” and “number of social medias” used for [ Idea + 
Solutions VS. None], as well as “negative impact of disease” for [Idea VS. None] have p value < 0,05. 
Those two factors for all groups have p-value < 0,1. Other p-values are greater than 0,1. 
As indicated in Table S3, “Field of study”, “Location of Residence”, “Educational Level” and “Member 
of patient association or group” have a p-value of <0,05 for [Idea + Solutions VS. None] and [Solution 
vs. None] groups. Also, for those 2 groups, “Access to internet daily” and “Would like to join PI” have 
p value <0,1. “Location of residence” for [Idea vs. None] and [Solution vs. None] group have p-value 
of 0,03 and 0,009, respectively. Other p-values are greater than 0,1. 
Following our initial results, factors resulted in a p-value < 0,05 in either “idea”, “innovation” and “idea 
+ innovation” groups are further analysed, and mean values (scale and ordinal factors) and percentages 
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(nominal factors and sub-factors) are presented in Table 16. As indicated, the negative impact of disease 
is higher (3,33-3,44) for “Idea” (p=0,007),  “Solution” (p=0,070) and “Idea+ Solution” (p=0,003) groups 
compared with “Non-innovator” group (3,12); the number of social media used is also higher (2,56-2,58) 
for all 3 innovative groups compared with “Non-innovation” group (2,34), and has stronger effect on 
“Idea+ Solution” group (p=0,016); a significantly higher % of the respondents study natural science for 
the “Solution” group (30,88%) and “Idea+ Solution” group (15,56%) compared with “Non-innovator” 
group (9,26%, p=0,000). For geographical location, a significantly higher % of respondents in all 3 
innovative groups (44,78%-47,06%) live in key cities compared with “Non-innovator” group (30,79%), 
and on the opposite, a obviously lower % of respondents in all 3 innovative groups (2,94-5,97%) 
compared with “Non-innovator” group (15,53%), with p-values of 0,003 (“Idea”), 0,009 (“Solution”) 
and 0,000 (“Idea+ Solution”), respectively; a greater % of the respondents in “Solution” group (26,47%) 
and “Idea + Solution” group (17,78%) hold a master degree and above, which highly exceed the “Non-
innovator” group (4,36%, p=0,000), and in those 2 innovative groups, a much higher % of respondents 
(33,82% for “Solution” group and 22,22% for “Idea+ Solution” group) are a member of patient 
association group, compared with less than 10% (9,81%) in the “Non-innovator” group (p = 0,000). 
In contrast, studying technology and holding a bachelor’s degree don’t exhibit an effect on PI (p>0,1). 
Factors Parameters Ideas Solutions Ideas + 
Solutions 
None 
Negative Impact 
of Disease 
p 0,007* 0,070*** 0,003* - 
Mean 3,44 3,33 3,39 3,12 
No. of social 
media used 
p 0,054*** 0,080*** 0,016** - 
Mean 2,58 2,56 2,57 2,34 
 
Field of Study 
p 0,378 0,000* 0,000* - 
Science (%) 8,96% 30,88% 15,56% 9,26% 
Technology (%) 34,33% 22,06% 31,06% 28,14% 
Location of 
Residence 
p 0,030** 0,009* 0,000* - 
Key cities (%) 44,78% 47,06% 45,93% 30,79% 
Countryside (%) 5,97% 2,94% 4,44% 15,53% 
 
Educational Level 
p 0,180 0,000* 0,000* - 
Bachelor (%) 68,66% 61,76% 65,19% 63,22% 
Master + (%) 8,96% 26,47% 17,78% 4,36% 
Member of patient 
association group 
p 0,872 0,000* 0,000* - 
Member (%) 10,45% 33.82% 22,22% 9,81% 
Table 16. Influencing factors and sub-factors for PI activities  
(Calculated using 1-way ANOVA (with post-hoc) and Chi-square analysis in SPSS;  
*p<0,01, **p<0,05, ***p<0,1; Green: with higher value/ %, Yellow: with lower value/ %) 
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We’ve also analysed the effect of 15 types of disease between different groups, of which heart disease/ 
CVD have a p-value < 0,01 for “idea” group and malnutrition have p-value < 0,5 for “innovation” group.  
 
 
4.3 Discussion 
4.3.1 Online-searched Chinese PI activities 
Our research results have clearly indicated that, similar to the finding from developed countries and 
other developing countries, PI activities of different categories (patient, caregiver and collaborator) are 
actively happening in China. Upon initial screening, a total of 45 efficient PI solutions were identified, 
with almost an equal number of solutions (~15) in each category. 
It is worth mentioning that, during our research process, we’ve frequently encounter examples that 
Chinese nurses, doctors and scientists have developed solutions (very often in their free time) to improve 
the patients’ treatment and comfort. In addition, we’ve found some innovative and effective solutions 
nevertheless, in which the patient didn’t take an active role in the innovation process. Those solution are 
not the focus of our research but may as well provide valuable information and help other patients. 
An interesting finding is that almost 95% of the effective PIs are developed by male innovators, 
indicating that male tend to be far more likely to bring an innovative idea into practice in China. In terms 
of geographical location, PI occur both among local residents and Chinese people living in overseas. 
The quality of online-searched PI activities varies. According to the rating results, 3/5 among them are 
considered to be good examples and ~90% of the solutions are acceptable (Good + Ordinary examples). 
In the collaborator category there is no limited examples, which possibly owing to the higher competence 
and/ or availability of collaborator relative to patients and caregivers. Some of the sectors such as 
automatic turning bed are overcrowded, with 10 out of 45 solutions belong to this category. 
In general, the 45 PI solutions we’ve found so far are quite similar to the existed ones on the PI platform, 
many of them are commented as “interesting” and “meaningful” according to the professionals working 
at Patient Innovation, and 20 are already shared on the PI platform. 
Most of those PI solutions took great effort and a certain amount of time, the innovator strives to improve 
it consistently, the majority of them have won awards and reported by media, and more importantly, the 
innovator is willing to share with other patient in need, either personally or commercially. 
 
4.3.2 Survey among Chinese patients and caregivers 
In general, our survey results have indicated a great diversity and a relatively active level of PI activities 
(innovative ideas and solutions from patient and caregivers) in China. Of the 502 respondents, 174 
(34,7%, 79 patients and 95 caregivers) have reported having an innovative idea or solution. The most 
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common type of idea or solution is “behaviour/ habit/ strategy” (50,2%), and more than 1/6 are 
“treatment/ therapy” or “food/ drink/ natural product”, and medical equipment accounts for 9,2%. A 
number of self-reported ideas and solutions are completely nonsense or thoughts that are hardly valuable, 
nevertheless, 136 (77,6%) of the ideas and solutions are considered as valid PI examples and 59 (33,9%) 
are considered as good PI examples according to medical specialists. Our further analysis is based on 
those screened, valid examples (67 ideas and 68 solutions). 
For the 67 respondents who have innovative ideas, 3/4 respondents have only thought about the idea and 
1/4 have specified it in a drawing/ text or have ever tried. Communication of the idea are more likely to 
happen, 3/4 have ever talked to other people, mostly with family members, other patients and friends. 
Interestingly, 3 (4,7%) have talked with the doctors. The respondents also reported several reasons that 
prevent them from implementing the idea, more than half perceived their idea “difficult to execute”, and 
more than 1/3 have time/ physical/ economical constraints. Sometimes respondents were also 
demotivated by others who think the idea is “not interesting”.  
For the 68 respondents who have innovative solutions (innovators), the majority have invested 
considerable time and money on developing the solution, with 35,3% took more than 2 years and 33,8% 
cost over 1000 EUR (converted from local currency). The innovators have also reported significant 
improvement of life quality (1,18 based on a 1-7 scale) after the innovation versus original medical 
treatments. 95,6% of innovators have received help from other people, in most situations are family and 
friends, and some are also helped by students and companies. Similarly, 95,6% of the innovators have 
been actively learning new knowledge during the innovations. 
Diffusion of innovations is also significant for innovators, 94,1% have discussed or showed their 
innovation to others, although unfortunately only 1 have talked to the doctor. Those innovations also 
generate public awareness, 19,1% have participated in competition/ exhibition or reported by media but 
the rest 55 have not yet known to the public. Moreover, 98,5% of the innovators are willing to share 
with other patients and 27.9% of innovations have already worked on others. 
Most innovators hold a positive attitude towards their innovation, such as planning to improve further 
(61,8%), would like to share for free or marginal cost (42,6%), which is in line with the findings in user 
innovation area (von Hippel, 2011). Many innovators also felt proud and improved confidence (35,3%). 
Our research also revealed some business potentials out of those innovations. Although only 7,4% are 
planning to start business or collaborate with manufacturer, 66,2% would like to apply for patents and 
11,8% have applied for patents already.  
We’ve achieved interesting results upon analysing the factors that possibly affect PI activities in China. 
In general, respondents with a higher negative disease impact (p<0,01) and living in key cities (p<0,05) 
are likely to have an innovative idea, such results are quite understandable as disease might stimulates 
the desire for innovation and respondents living in key cities have better access to information and 
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activities including those related to innovation. Respondents studying natural science (p<0,001), holding 
a master degree or above (p<0,001), living in key cities (p<0,01) and being a member of patient group/ 
association (p<0,001) are likely to have an innovative solution. Quite reasonably as well, as those are 
all likely to act as promoting factors for implementing an idea, as respondents with those features are 
probably have more professional knowledge and expertise to develop a solution, and/ or more motivated 
or have more resources for putting an idea into practices. Living in the countryside act as a negative 
factor of both have an idea (p<0,05) and having a solution (p<0,01), probably due to poor access to 
information and other resources or maybe economical constraints. 
If we consider the respondents having either an idea or innovation in the same group (idea + solution), 
all the factors mentioned above (negative impact of disease, living in key cities, having a master degree 
or above, study natural science and being a member of patient group/ association, living in countryside) 
are highly likely to impact PI activities in China (p<0,005). Besides, the number of social medias used 
indicate a higher likelihood of PI activities in China for “Idea+ Solution” group (p<0,05). Factors with 
a relatively weak effect (p<0,1) on PI are “have access to internet daily” and “would like to join the PI 
community”. Besides the aforementioned reasons, the last 3 factors possibly indicate willingness and 
easiness to exchange information and sharing, which are likely to contribute to innovation activities. 
Not completely as expected, factors such as the number of diseases suffered, disease duration, treatment 
efficiency, increase in monthly expense, marital status and employment status don’t seem to be the 
influential factors of PI activities in China according to our study. Take into consideration of overall 
survey results, a certain number of patients and caregivers would find it comfortable to follow the 
advices from doctors and prefer to keep the Status quo than to challenge the professional medical 
treatment they’ve received. Getting married and in employment also might affect in two opposite ways 
for innovation: more support and stronger economical basis, but less personal time for innovation. 
Finally, most of the 15 diseases (based on our classification) don’t seem to affect PI activities in China, 
only heart diseases/ CVD has significant effect (p<0,01) on “Idea” group and malnutrition has moderate 
effect (p<0,05) on “Solution” group. A possible reason could be most of those are common disease types 
with matured treatment plans, and thus demotivating patients and their caregivers from seeking for 
alternative, innovative solutions. In the future, it would be meaningful to investigate further on rare 
diseases and diseases that lack of efficient treatments, which patients and their caregivers possibly have 
more innovative motivation to improve treatment and life quality. 
 
4.3.3 Comparison of PI activities in China and developed countries 
Overall, our research has demonstrated the diversity of innovations in Chinese patients and caregivers. 
It would also be interesting to compare those innovations with those from developed countries, which 
were systematically studied and practical examples are shared on the PI platform. 
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For the online-searched solutions, we’ve acquired a total of 45 examples that we consider qualified as 
PI activity, of which 28 are “Good Examples” suitable to share on the PI website. (~20 have already 
shared) However, this number is relatively small consider the huge population base (1,4 Bio) in China, 
in comparison to more than 100 solutions from USA, UK or Europe respectively on the PI platform. By 
comparing with existed solutions on he PI platform, our overall impression is that the Chinese solutions 
are relatively low-end, low-cost, simple and somehow less innovative than the solutions in developed 
countries. For instance, the fast-lifting wheel chair developed by a Chinese boy functionate quite well, 
but indeed appear to be simpler, economic and less advanced than the other type of wheelchairs 
including 3D-printed wheelchair, eye-controlled wheelchair and stand-up wheelchair from developed 
countries. However, those simple solutions would also create great value to the patients and others in 
need, and simple / low-cost solutions would be also advantageous to be followed remotely. 
For the survey among Chinese patients and caregivers, although the 502 patients involved in this sample 
have an average age of ~50 and includes a certain % of elder people, which may be different from the 
related survey of 496 patients and caregivers in Portugal (Oliveira et al., 2015), where the patient have 
an average of 33 and the less % of respondents are employed or holding a university degree. However, 
our studies has indicated some similarities between the PI activities in China and Portugal. For instance, 
only part of the self-reported solutions is considered to be useful or innovative. Initial screening would 
remove un-novel examples, and less than half of the novel examples are considered to be relatively 
useful (For the Chinese survey, if we only account for solutions but not ideas), the solution also spread 
among different categories (products, services, etc). In additions, innovators are likely to share the 
solutions with other patients but very few (less than 5%) choose to share with the doctors. 
Nevertheless, our research suggested the activity level of PI in China is lower than those in Portugal, as 
only 70 out of ~500 are actually creating innovations, even considering the respondents with only ideas, 
a total of 175 (34,9%) are innovators, which is significantly lower than 53% of self-reported innovators 
in Portugal. Communication of PI solutions to other patients also exhibits huge difference: only 23,5% 
of Chinese innovators have shown the innovation to other patients (however, 2/3 have shown to their 
family), compared with ~90% of the Portuguese innovators have shown it to other patients. 
For the influencing factors to PI activities, we’ve also found interesting patterns by comparing the two 
countries: For both Chinese and Portuguese innovators, disease burden and educational level would have 
a significant effect on innovators, whereas marital status, employment status and disease duration has 
no effect. A factor that showed differences between two countries are being a member of patient 
association or group, which have an effect on Chinese innovators (likely to promote innovations from 
patients and caregivers) but without effect for Portuguese innovators.  
Unfortunately, due to the missing of gender and age information of ~30% of the caregivers, the influence 
of gender and age would not be studied and compared in our current study, but deserves to explore 
further and compared with innovators from other countries in our future studies. 
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Lastly, valuable components would be added to our research by studying the specific innovations and 
ideas from our survey and compared the results from Portuguese PI survey. 
 
5 Conclusions 
5.1 Implication of our Research 
  
Online available PI Activities 
Extent 
Actively exist for different categories (patient, caregiver, collaborator). Absolute 
number is low consider the huge Population Base in China. 
Quality 
Relatively low-end, simple, low-cost solutions. Quality varies but most are 
acceptable. Some are innovative and inspiring. 
 
Survey Among Patients and Caregivers 
General 
Actively exist with 1/3 self-reported innovators, but only part of them is 
qualified.13,3% respondents have an idea and 13,5% have a solution. 
Respondents 
with ideas 
Only 1/4 have specified in text/ draft or have ever tried, but 3/4 have talked to 
others, mainly family and other patients (very few to doctors), many constraints 
restrictions hinder the implementation of ideas. 
Respondents 
with innovations 
Many invested time and money, 72% improved in life quality after the innovation. 
94% have shown or talked to others, mainly family and other patients (very few 
to doctors). Some awareness by public. Positive attitude and willingness to share, 
28% shared and worked on others. Certain commercial potential exists. 
Influencing 
factors 
Idea: negative disease impact, living in big cities, not living in countryside 
Solution: study natural science, holding a master degree and above, being a 
member of patient group/ association, living in big cities but not countryside 
Idea + Solution: All above factors, maybe no. of social media used etc. 
*CVD/ Heart disease affects “idea” group; malnutrition maybe affects innovation group. 
 
Survey Among Patients and Caregivers 
Online (VS. US/ 
UK/ Europe) 
Lower active level in China. Relatively simple, economic and less advanced in 
technology (less innovative), either for general impression or similar solutions. 
Survey 
(VS.Portugal) 
Similarities in the diversity, quality and influencing factors (as well as factors 
without significance). Portugal has a higher level of PI activities and significantly 
greater % of innovators sharing solutions with other patients. 
Table 17. Main findings of PI activities in China 
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In general, we are inspired throughout different stages of our research project, from which we have 
observed the innovative inventions of patients and caregivers from various dimensions. The main 
findings of our research project are summarized in Table 17. To our best knowledge, this is the first 
study in the field of patient innovation in China, and we believe our research will add up crucial elements 
to the user innovations in the healthcare sector, as well as improve sharing on Patient Innovation 
platform between innovators from China and other countries. 
 
5.2 Limitations of Research 
Our research study based on the innovation activities by patients and caregivers in China have several 
limitations, which include: 
1) Our samples could hardly in representative of the overall Chinese population: In the multiple-
case study, the samples are all collected online, which means only the solutions that are shared or 
reported publicly are collected, however those the innovator have not yet shared had been omitted; in 
the survey among patient and caregivers in China, the samples are collected from a database of more 
than 2 million Chinese users, however, those people are probably more likely to participate in online 
surveys and complete it on a timely manner. Those may create a modest conservative bias in our findings 
regarding innovation activities among Chinese patients and caregivers. 
2) Our sample size was still relatively small due to some constraints: Despite the diversity and 
richness of resources, our research would still have been benefited from a bigger sample size. We were 
expecting to collect more samples for online-available solutions, but according to our definition we have 
to stick to the 45 effective PI solutions according to our best knowledge; For online survey we’ve 
collected more than 500 comprehensive examples, nevertheless, as only 15% have move the innovation 
idea forward, sample size is still limited for analysing innovators that are developing or have developed 
a solution. 
3) Subjective and self-reported data may result in some inaccuracies: The survey includes a certain 
amount of self-reported data. For open questions such as description of innovation, error may exist 
compared with real situation; The measurement of effectiveness of treatment, and patients’ quality of 
life before and after the innovation are self-reported data, in which the standards may be biased between 
individuals; The rating and classification of innovations were done with the help of medical 
professionals, but still could no fully exclude subjective elements. 
Despite the above limitations, we nonetheless consider that our research has contributed to the field of 
user innovation in the global healthcare sector. 
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5.3 Future Research  
We are pleased to see that the previous research work provided more possibilities for the next stage. In 
addition, we would suggest the following directions of investigation in the future: 
1) It would be meaningful to establish contact with patient associations, patient communities and patient 
forum/ groups, through which we are able to access a larger number of patients and caregivers for first-
hand data and information, and focus on specific types of disease when necessary; 
2) Communication with the innovators: due to the constraints, our currents study mainly obtained 
information passively. It would be extremely helpful if we overcome this barrier in the future and have 
more interactions (emails, phone interviews, groups discussions) with the patient and caregivers, and we 
strongly believe more detailed and accurate information will be obtained; 
3) The following areas are worthy of attention: Collaborators, which is also an important category for 
the PI activities in China; Parents whose kids are born with a suffering from a chronic/ serious disease, 
which we expected to have potential findings though our current works has found very few examples; 
4) Lastly, we strongly believe that the PI activities from China would add value to the PI community, 
and in the future, we will make our effort to have more Chinese contents on the PI platform, and actively 
promote the sharing of solutions between Chinese PI innovators and those from other countries. 
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C.    Survey for Patient Innovation 
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D. Fixation of PI China Survey Data 
 
1) Samples missing important data or not in the range of our analysis are removed 
#747 – No disease type 
#478 – Belongs to the collaborator type 
#81 – Missing Demographic and ICT information 
#57, #51 – Missing ICT information 
 
2) Samples missing genders of the patients are recovered based on relationship information 
#792, #778, #674, #668, #651, #629, #565, #511 are recovered                                                                                                           
#541, #561 – Could not be recovered, so we’ve removed them  
 
Besides, we’ve recovered the birth year and gender information in Q25 and Q26, when the respondent 
is a patient, however, this method does not apply to the case where the respondent is a caregiver. Due to 
the missing information of birth year and gender information of the respondents and other constraints, 
we’ve finally decided to exclude the gender and birth year of respondents in our analysis.  
 
7 out of 509 samples in PI China survey were removed, and the rested 502 are applied for statistical 
analysis.  
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E. List of valid PI Examples from Survey 
 
Id Type Classification Description Rate 
620 Innovation A Treatment/ Therapy A method to completely 
cure diabetes 
PI - Good Example 
588 Innovation A Behaviour/ Habit/ 
Strategy 
Change life schedule to 
reduce frequency of 
occurrence 
PI - Ordinary 
Example 
430 Innovation A medical equipment Heart Starter PI - Good Example 
323 Innovation A Behaviour/ Habit/ 
Strategy 
Avoid spicy and salty 
food, light diet 
PI - Good Example 
464 Innovation A food/ drink/ natural 
product 
Water PI - Good Example 
142 Innovation A Behaviour/ Habit/ 
Strategy 
Take care of health PI - Good Example 
745 Innovation A food/ drink/ natural 
product 
A drink to treat diabetes PI - Good Example 
60 Innovation A Behaviour/ Habit/ 
Strategy 
Reduce a certain type of 
antihypertensive drugs 
PI - Good Example 
50 Innovation A Treatment/ Therapy Combined with medical 
treatment 
PI - Good Example 
463 Innovation A Treatment/ Therapy Medication PI - Ordinary 
Example 
709 Innovation A medical equipment Respirator to treat athema PI - Good Example 
678 Innovation A food/ drink/ natural 
product 
Reduce salt intake PI - Ordinary 
Example 
460 Innovation A Treatment/ Therapy A treatment method aim 
to alleviate the pain 
PI - Good Example 
697 Innovation A Treatment/ Therapy Medical treatment in 
combination with diet 
PI - Ordinary 
Example 
110 Innovation A food/ drink/ natural 
product 
A food that help to 
maintain a stable 
condition 
PI - Good Example 
129 Innovation A medical equipment Chemotherapy apparatus PI - Good Example 
696 Innovation A Behaviour/ Habit/ 
Strategy 
Balanced nutrition & low 
sugar diet 
PI - Good Example 
395 Innovation A Treatment/ Therapy Foods that can ease 
diabetes in daily life 
PI - Good Example 
205 Innovation A food/ drink/ natural 
product 
A drink that could cure 
the disease 
PI - Good Example 
76 Innovation A Behaviour/ Habit/ 
Strategy 
Through exercise and 
sports 
PI - Good Example 
351 Innovation A Behaviour/ Habit/ 
Strategy 
Take more walks PI - Ordinary 
Example 
152 Innovation A Behaviour/ Habit/ 
Strategy 
Exercise everyday PI - Ordinary 
Example 
13 Innovation A Treatment/ Therapy Combination of Western 
and Chinese medicine 
treatment 
PI - Ordinary 
Example 
524 Innovation A Behaviour/ Habit/ 
Strategy 
Proper diet and living 
style 
PI - Good Example 
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141 Innovation A Behaviour/ Habit/ 
Strategy 
Chinese medicine assisted 
with proper diet 
PI - Good Example 
658 Innovation A medical equipment A portable device to cure 
Asthma 
PI - Ordinary 
Example 
384 Innovation A Treatment/ Therapy Habits that reduce patient 
from suffering 
PI - Ordinary 
Example 
300 Innovation A Behaviour/ Habit/ 
Strategy 
Relieve diabetes PI - Ordinary 
Example 
273 Innovation A Behaviour/ Habit/ 
Strategy 
Not specified PI - Ordinary 
Example 
654 Innovation A medical equipment Highly-efficient treatment 
device 
PI - Good Example 
689 Innovation A Behaviour/ Habit/ 
Strategy 
Reasonable health (?) PI - Ordinary 
Example 
556 Innovation A Behaviour/ Habit/ 
Strategy 
Pay attention to diet PI - Good Example 
700 Innovation A Behaviour/ Habit/ 
Strategy 
Keep warm and avoid 
strenuous exercise 
PI - Ordinary 
Example 
640 Innovation A Treatment/ Therapy Combination of Western 
and Chinese Medicine/ 
Treatment 
PI - Ordinary 
Example 
380 Innovation A Behaviour/ Habit/ 
Strategy 
Diet PI - Ordinary 
Example 
286 Innovation A Behaviour/ Habit/ 
Strategy 
Proper & reasonable diet PI - Ordinary 
Example 
54 Innovation A Behaviour/ Habit/ 
Strategy 
Adequate physical 
exercises 
PI - Ordinary 
Example 
20 Innovation A Behaviour/ Habit/ 
Strategy 
Exercise more, take 
proper type of physical 
exercise 
PI - Ordinary 
Example 
526 Innovation A Treatment/ Therapy Hypnosis PI - Good Example 
427 Innovation A Behaviour/ Habit/ 
Strategy 
Regulate diet habit PI - Good Example 
194 Innovation A Behaviour/ Habit/ 
Strategy 
Strengthen your physical 
capacity 
PI - Good Example 
21 Innovation A Treatment/ Therapy Relieve the condition 
(Pharyngitis) 
PI - Good Example 
670 Innovation A Behaviour/ Habit/ 
Strategy 
Acupressure PI - Ordinary 
Example 
130 Innovation A food/ drink/ natural 
product 
Food that helps alleviate 
the condition 
PI - Ordinary 
Example 
542 Innovation A Behaviour/ Habit/ 
Strategy 
Exercise more PI - Ordinary 
Example 
450 Innovation A food/ drink/ natural 
product 
Hypotensive tea PI - Ordinary 
Example 
712 Innovation A food/ drink/ natural 
product 
Fruit & vegetable drink PI - Good Example 
724 Innovation A Behaviour/ Habit/ 
Strategy 
Running/ Jogging PI - Ordinary 
Example 
183 Innovation A Behaviour/ Habit/ 
Strategy 
A reasonable diet and 
regular exercise 
PI - Ordinary 
Example 
222 Innovation A Behaviour/ Habit/ 
Strategy 
Pay attention to diet PI - Good Example 
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540 Innovation A Behaviour/ Habit/ 
Strategy 
More exercise, less desire 
and intake of unhealthy 
food 
PI - Good Example 
221 Innovation Others Not specified PI - Good Example 
74 Innovation A Treatment/ Therapy Food therapy PI - Good Example 
3 Innovation A Behaviour/ Habit/ 
Strategy 
Good living habit & 
customs 
PI - Ordinary 
Example 
163 Innovation A food/ drink/ natural 
product 
Exercise and food therapy PI - Ordinary 
Example 
656 Innovation A Behaviour/ Habit/ 
Strategy 
Pay attention to weather 
changes 
PI - Good Example 
650 Innovation A Behaviour/ Habit/ 
Strategy 
Exercise deligently and 
properly 
PI - Good Example 
327 Innovation A Behaviour/ Habit/ 
Strategy 
Enable patient to live 
happily in the hospital (?) 
PI - Good Example 
299 Innovation A Behaviour/ Habit/ 
Strategy 
Ensure peace of mind, 
wear a mask, keep away 
from dust 
PI - Good Example 
225 Innovation A Behaviour/ Habit/ 
Strategy 
Pay attention to hygiene, 
exercise more daily 
PI - Good Example 
70 Innovation A Behaviour/ Habit/ 
Strategy 
Plan a better living style PI - Good Example 
47 Innovation A food/ drink/ natural 
product 
Polycarpaea corymbosa 
(L.) Lam. 
PI - Good Example 
37 Innovation A Behaviour/ Habit/ 
Strategy 
Pay attention to the diet 
(modify according to 
one's ongoing condition) 
PI - Good Example 
5 Innovation A Behaviour/ Habit/ 
Strategy 
Oxygen therapy PI - Good Example 
642 Innovation A Behaviour/ Habit/ 
Strategy 
Eat more fruits and 
vegetables 
PI - Ordinary 
Example 
252 Innovation A Behaviour/ Habit/ 
Strategy 
Eat less salt PI - Ordinary 
Example 
188 Innovation A Behaviour/ Habit/ 
Strategy 
Work and rest regularly PI - Ordinary 
Example 
172 Innovation A Behaviour/ Habit/ 
Strategy 
Eat more nutritional food PI - Ordinary 
Example 
714 Idea A medical equipment A portable device to 
prevent occurance/ onset 
PI - Good Example 
706 Idea A Behaviour/ Habit/ 
Strategy 
Meditation PI - Good Example 
682 Idea A Behaviour/ Habit/ 
Strategy 
Improve gout through a 
set of useful exercises 
PI - Good Example 
671 Idea A Behaviour/ Habit/ 
Strategy 
Pay attention to diet and 
mood 
PI - Good Example 
662 Idea A Behaviour/ Habit/ 
Strategy 
Avoid strong emotions 
(e.g. anger) 
PI - Good Example 
473 Idea A medical equipment A device to help patient 
breath smoothly 
PI - Good Example 
405 Idea A food/ drink/ natural 
product 
Spirulina PI - Good Example 
370 Idea A food/ drink/ natural 
product 
Celery (Lower blood 
pressure) 
PI - Good Example 
 49 
 
349 Idea A medical equipment A wheelchair that could 
monitor the body status 
PI - Good Example 
215 Idea A medical equipment Asthma pressure reducer PI - Good Example 
211 Idea A Behaviour/ Habit/ 
Strategy 
Proper/ reasonable diet 
and exercise consistently 
PI - Good Example 
116 Idea A Behaviour/ Habit/ 
Strategy 
Auxiliary diet and take 
more exercise 
PI - Good Example 
100 Idea A Behaviour/ Habit/ 
Strategy 
Acupuncture and massage PI - Good Example 
92 Idea A medical equipment Ventilator PI - Good Example 
77 Idea A medical equipment Auto detection device PI - Good Example 
34 Idea A Behaviour/ Habit/ 
Strategy 
The influence of lifestyle 
on diabetes, and how to 
improve 
PI - Good Example 
22 Idea A Behaviour/ Habit/ 
Strategy 
Healthy diet, formulating 
scientific & reasonable 
recipes 
PI - Good Example 
18 Idea A Behaviour/ Habit/ 
Strategy 
Healthy eating, regular 
lifestyle, diligent exercise 
PI - Good Example 
729 Idea A Behaviour/ Habit/ 
Strategy 
Take more exercise PI - Ordinary 
Example 
699 Idea A food/ drink/ natural 
product 
Food that contains less 
sugar but delicious 
PI - Ordinary 
Example 
677 Idea A food/ drink/ natural 
product 
Eat more fruit and 
vegetables, etc. 
PI - Ordinary 
Example 
666 Idea A Behaviour/ Habit/ 
Strategy 
Go to bed early and get 
up early 
PI - Ordinary 
Example 
661 Idea A Behaviour/ Habit/ 
Strategy 
Eat less meat PI - Ordinary 
Example 
660 Idea A Behaviour/ Habit/ 
Strategy 
Keep positive mood and 
work/ sleep properly 
PI - Ordinary 
Example 
619 Idea A Behaviour/ Habit/ 
Strategy 
Feet bath everyday PI - Ordinary 
Example 
602 Idea A food/ drink/ natural 
product 
A food that can cure 
laryngitis 
PI - Ordinary 
Example 
590 Idea A medical equipment A device to relieve pain 
of patients 
PI - Ordinary 
Example 
534 Idea A food/ drink/ natural 
product 
Eat adequate food to 
improve the condition, 
strictly follow a plan 
PI - Ordinary 
Example 
499 Idea A Treatment/ Therapy Reduce the amount of 
exercise 
PI - Ordinary 
Example 
498 Idea A Behaviour/ Habit/ 
Strategy 
Avoid from strong 
emotions 
PI - Ordinary 
Example 
482 Idea A Behaviour/ Habit/ 
Strategy 
Free from alcohol PI - Ordinary 
Example 
475 Idea A Behaviour/ Habit/ 
Strategy 
Exercise, take a walk, 
fitness 
PI - Ordinary 
Example 
456 Idea A food/ drink/ natural 
product 
Plants in the nature that 
can improve the 
condition/ health 
PI - Ordinary 
Example 
448 Idea A Behaviour/ Habit/ 
Strategy 
Go to bed early and get 
up early 
PI - Ordinary 
Example 
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447 Idea A Behaviour/ Habit/ 
Strategy 
Food therapy PI - Ordinary 
Example 
444 Idea A Behaviour/ Habit/ 
Strategy 
Diet or rest properly to 
regulate blood pressure 
PI - Ordinary 
Example 
426 Idea A Behaviour/ Habit/ 
Strategy 
Keep health care/ 
wellness 
PI - Ordinary 
Example 
424 Idea A Behaviour/ Habit/ 
Strategy 
Go to bed early and get 
up early 
PI - Ordinary 
Example 
386 Idea A Treatment/ Therapy Exercise Improves 
Immunity 
PI - Ordinary 
Example 
352 Idea A Behaviour/ Habit/ 
Strategy 
Eat and sleep on time/ 
regularly 
PI - Ordinary 
Example 
346 Idea A Behaviour/ Habit/ 
Strategy 
Keep a good habit of 
exercise 
PI - Ordinary 
Example 
328 Idea A food/ drink/ natural 
product 
Apple PI - Ordinary 
Example 
317 Idea A Behaviour/ Habit/ 
Strategy 
Sleep early and get up 
early 
PI - Ordinary 
Example 
289 Idea A Behaviour/ Habit/ 
Strategy 
Take exercises often PI - Ordinary 
Example 
277 Idea A food/ drink/ natural 
product 
Eat sugar-free food PI - Ordinary 
Example 
265 Idea A Behaviour/ Habit/ 
Strategy 
Wear a mask when going 
outside 
PI - Ordinary 
Example 
260 Idea A Treatment/ Therapy Avoid taking medicine, 
relieve by massage 
instead 
PI - Ordinary 
Example 
232 Idea A Treatment/ Therapy Accupunture treatment PI - Ordinary 
Example 
228 Idea A Behaviour/ Habit/ 
Strategy 
On diet (Reduce intake) PI - Ordinary 
Example 
227 Idea A Behaviour/ Habit/ 
Strategy 
Go to bed early and get 
up early 
PI - Ordinary 
Example 
207 Idea A Behaviour/ Habit/ 
Strategy 
Eat more fruit PI - Ordinary 
Example 
202 Idea A Behaviour/ Habit/ 
Strategy 
Reduce salt intake PI - Ordinary 
Example 
200 Idea A food/ drink/ natural 
product 
Inhibition of asthma PI - Ordinary 
Example 
193 Idea A Behaviour/ Habit/ 
Strategy 
Conduct a sugar-free diet 
plan 
PI - Ordinary 
Example 
180 Idea A food/ drink/ natural 
product 
A food therapy method PI - Ordinary 
Example 
165 Idea A Behaviour/ Habit/ 
Strategy 
Exercise more PI - Ordinary 
Example 
161 Idea A Behaviour/ Habit/ 
Strategy 
Eat light food, exercise 
more 
PI - Ordinary 
Example 
147 Idea A food/ drink/ natural 
product 
Fruit PI - Ordinary 
Example 
114 Idea A Treatment/ Therapy Nutritional diet PI - Ordinary 
Example 
109 Idea A Behaviour/ Habit/ 
Strategy 
Take more exercise PI - Ordinary 
Example 
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99 Idea A food/ drink/ natural 
product 
Healthy food/ food 
therapy 
PI - Ordinary 
Example 
87 Idea A medical equipment A device to relieve pain PI - Ordinary 
Example 
64 Idea A Behaviour/ Habit/ 
Strategy 
Eat foods that help to 
improve coronary heart 
disease every day 
PI - Ordinary 
Example 
53 Idea A Behaviour/ Habit/ 
Strategy 
Healthy food/ diet PI - Ordinary 
Example 
52 Idea A Behaviour/ Habit/ 
Strategy 
Improve living habits PI - Ordinary 
Example 
38 Idea A Behaviour/ Habit/ 
Strategy 
Good and health living 
habits 
PI - Ordinary 
Example 
10 Idea A Behaviour/ Habit/ 
Strategy 
Diet and healthy recipes PI - Ordinary 
Example 
Table S1. List of valid PI activities in China (from survey)  
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F.    Influencing factors of PI Activities in China 
Respondents with Innovative ideas and Innovative solutions were considered as either independent or 
same group, the three groups included in our analysis are [Ideas VS. None] and [Solutions VS. None] 
and [Idea + Solutions VS. None] (in SPSS, 4 variables for group identification were established to reduce 
errors). 
For scale and ordinal variables, we’ve used 1-way ANOVA analysis plus post-hoc method, therefore 
[Ideas VS. None] and [Solutions VS. None] were calculated in one model to reduce Type I error, as 
shown in Table S2. 
 
Nominal variables (including disease type) were analysed using Chi-square, results are shown in Table 
S3 and S4, where [Ideas VS. None] and [Solutions VS. None] were calculated in 2 models as the 
difference between “Innovative Ideas” and “Innovative Solutions” are not in the range of our study.  
P-Value Ideas Solutions Ideas + Solutions 
Marital Status 0,175 0,734 0,333 
Field of Study 0,378 0,000* 0,000* 
Employment Status 0,132 0,167 0,121 
Location of Residence 0,030** 0,009* 0,000* 
Educational Level 0,180 0,000* 0,000* 
Member of Patient 
association of group 
0,872 0,000* 0,000* 
Access to Internet 0,197 0,188 0,077*** 
Would like to join PI 0,142 0,228 0,073*** 
Table S3. Significance of Nominal Factors for PI activities  
(Calculated using Chi-square analysis in SPSS; *p<0,01, **p<0,05, ***p<0,1) 
 
  
P-Value Ideas Solutions Ideas + Solutions 
No, of diseases 0,458 0,300 0,241 
Disease Duration 0,321 0,911 0,733 
Negative Impact of Disease 0,007* 0,070*** 0,003* 
Treatment Efficiency 0,646 0,211 0,259 
Increase in expense 0,266 0,124 0,081*** 
No. of social media used 0,054*** 0,080*** 0,016** 
Table S2. Significance of Scale and Ordinal Factors for PI activities  
(Calculated using 1-way ANOVA (with post-hoc) analysis in SPSS; *p<0,01, **p<0,05, ***p<0,1)  
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P-Value Ideas Solutions Ideas + Solutions 
Hypertension 0,555 0,235 0,243 
Hyperlipemia 0,776 0,787 0,720 
Hyperglycaemia 0,391 0,387 0,223 
Diabetes 0,219 0,368 0,849 
Heart diseases/ CVD 0,002* 0,547 0,091*** 
Asthma 0,695 0,843 0,898 
Osteoporosis 0,218 0,660 0,266 
Cervical/ lumbar diseases 0,595 0,454 0,932 
Rheumatoid/ rheumatism  0,686 0,219 0,620 
Otolaryngology disease 0,717 0,282 0,611 
Gastrointestinal disease 0,555 0,920 0,753 
Respir track inflammation 0,630 0,814 0,881 
Gout 0,521 0,839 0,576 
Malnutrition 0,932 0,032** 0,160 
Hepatitis/ other liver diseases 0,933 0,333 0,570 
Table S4. Significance of diseases for PI activities  
(Calculated using Chi-square analysis in SPSS; *p<0,01, **p<0,05, ***p<0,1) 
 
